Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. Its innovative, patented 3C Patch® System draws on the individual patient’s capacity to heal and is clinically proven to accelerate wound healing of chronic diabetic foot ulcers. Headquartered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the Danish 2018 EY Entrepreneur of the Year Award in the life science category. Our business model is supported by high quality RCT evidence published in The Lancet in September 2018 and a 2019 IWGDF Recommendation.
www.reapplix.com
www.reapplix.com
Location: Denmark, Birkerød
Employees: 11-50
Total raised: $3.03M
Founded date: 2008
Investors 2
| Date | Name | Website |
| 30.05.2022 | Lauxera Ca... | lauxera.co... |
| 05.08.2021 | Seed Capit... | seedcapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.09.2016 | - | $3.03M | - |
Mentions in press and media 4
| Date | Title | Description |
| 20.07.2023 | Reapplix wins 2023 Frost & Sullivan’s Best Practices Technology Innovation Leadership Award | “At Reapplix, our commitment to innovation and customer success comes directly from a passion to draw on the patient’s power to heal to improve patient’s lives." BIRKEROD, Denmark (PRWEB) July 20, 2023 Reapplix, a leading company speci... |
| 09.02.2022 | Paris-based Lauxera Capital Partners sets high stakes on health tech with $300 million maiden fund | Investment firm based in Paris and San Francisco, Lauxera Capital Partners announced the final closing of its first fund, Lauxera Growth I, at more than €260 million (approximately $300 million), making it one of the leading European funds ... |
| 27.09.2016 | Reapplix Raises €2.7M in Funding | Reapplix, a Birkerod, Denmark-based developer of device technology for tissue regeneration, raised €2.7m in funding. Backers included existing investors SEED Capital Denmark, Novo Seeds and Vækstfonden (The Danish Growth Fund). The company ... |
| - | Paris-based Lauxera Capital Partners sets high stakes on health tech with $300 million maiden fund | Investment firm based in Paris and San Francisco, Lauxera Capital Partners announced the final closing of its first fund, Lauxera Growth I, at more than €260 million (approximately $300 million), making it one of the leading European funds ... |